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OBJECTIVES We examined the procedural and 30-day clinical outcomes among patients receiving aspirin
and either ticlopidine or clopidogrel during coronary stenting.
BACKGROUND Ticlopidine-plus-aspirin has become standard antiplatelet therapy for the prevention of
thrombotic complications after coronary stenting. Clopidogrel has a similar mechanism of
action as ticlopidine, but both its efficacy and its safety as a pharmacologic adjunct to coronary
stenting have not been well described.
METHODS This single-center, prospective analysis examined the in-hospital procedural and 30-day
clinical outcomes among 875 consecutive patients undergoing coronary stenting who received
adjunctive aspirin and either clopidogrel (n 5 514; 58.7%) or ticlopidine (n 5 361; 41.3%)
therapy.
RESULTS Procedural success rates were similar among the clopidogrel- (99.6%) and ticlopidine-treated
patients (99.4%). Subacute stent thrombosis (i.e., .24 h #30 days) occurred in one
clopidogrel-treated (0.2%) and in one ticlopidine-treated (0.3%) patient (p 5 0.99). By 30
days following the index procedure, the combined rates of death, nonfatal myocardial
infarction and need for target vessel revascularization were similar among patients who
received either clopidogrel (2.1%) or ticlopidine (1.4%; p 5 0.57) therapy.
CONCLUSIONS In this analysis the antiplatelet combination therapy of aspirin-plus-clopidogrel was an
effective regimen for preventing thrombotic complications and major adverse cardiovascular
events among a broad spectrum of patients undergoing coronary artery stenting. (J Am Coll
Cardiol 1999;34:1884–90) © 1999 by the American College of Cardiology
In contemporary interventional cardiology, coronary stent-
ing has emerged as the predominant method of percutane-
ous coronary intervention (PCI). Early experience with
coronary stenting was associated with high rates of acute
and subacute stent thrombosis, which were observed to
occur in up to 20% of cases without anticoagulation (1,2).
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Attempts to suppress stent thrombosis using aggressive
anticoagulant regimens unfortunately contributed to excess
hemorrhagic and vascular access site complications and
prolonged hospitalization (3,4). The recognition of the
major contribution of platelet-mediated mechanisms to the
pathogenesis of stent thrombosis led to the evaluation of the
antiplatelet combination of aspirin-plus-ticlopidine, with
resultant stent thrombosis rates of ,1% and concomitant
reduced hemorrhagic complication rates.
Ticlopidine (Ticlid™), a member of the thienopyridine
class of antiplatelet agents, acts by blocking the platelet
adenosine diphosphate receptor, interferes with the binding
of von Willebrand factor to platelet receptors, and has
synergistic antiplatelet activity when used in combination
with aspirin (5,6). Recent reports (7,8) highlight the poten-
tial hematological toxicity (neutropenia and thrombotic
thrombocytopenic purpura) associated with even brief
courses of ticlopidine.
Clopidogrel (Plavix™), a new thienopyridine derivative
with a similar mechanism of action as ticlopidine, has been
shown to be an effective antiplatelet agent for patients with
cardiovascular disease (9), with a favorable tolerability and
safety profile. The incidence of severe neutropenia with
clopidogrel is similar to that with aspirin (0.04% vs. 0.02%,
respectively), and less than that reported with ticlopidine
(0.08% to 2.5%) (10). Unlike ticlopidine, thrombotic
thrombocytopenic purpura has not been reported with
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clopidogrel use. These findings have led to the proposal of
clopidogrel as a potentially “safer” alternative to ticlopidine;
however, the clinical efficacy and safety of the clopidogrel-
plus-aspirin antiplatelet combination during coronary stent-
ing is relatively unknown.
Thus, the purpose of this study was to compare the
in-hospital and 30-day procedural and clinical outcomes
among a broad spectrum of patients who received aspirin
and either clopidogrel or ticlopidine as adjunctive antiplate-
let therapy during coronary stenting.
METHODS
Study population. Demographic, procedural and outcome
information of patients undergoing a PCI at the Prairie
Heart Institute at St. John’s Hospital and the Heart Center
at Memorial Medical Center, Springfield, Illinois, were
prospectively entered into an electronic database. From this
database we examined a consecutive cohort of patients
undergoing elective or bail-out coronary stenting procedures
over a five-month period between March 1, 1998, until July
31, 1998. Analysis was performed on all patients who
received combination aspirin and either ticlopidine or clo-
pidogrel either prior to or immediately following the index
coronary stenting procedure.
Coronary procedures and adjunctive antiplatelet therapy.
Before balloon dilation, a heparin bolus was administered to
achieve an activated clotting time (ACT) of .200 and .300 s
among patients who did and did not receive glycoprotein
IIb/IIIa inhibitor (GPIIb/IIIa) antagonists, respectively. Sub-
sequent coronary artery stenting was performed using current
Food and Drug Administration-approved stents. Following
stent implantation, high-pressure ($12 atmospheres) balloon
inflation and use of larger balloon sizes were routinely per-
formed with the goal of achieving a post-stent balloon-to-
vessel ratio of 1.0 to 1.2:1. Use of intravascular ultrasound
following stent implantation was not routine. The use of pre-
and intra-procedural intracoronary nitroglycerin, postproce-
dural use of heparin, and the adjunctive use of platelet
GPIIb/IIIa inhibitors were left to the discretion of the indi-
vidual operators.
All patients received pretreatment with oral aspirin
(325 mg) prior to the procedure and continued daily
thereafter. Patients received either oral ticlopidine (250 mg
twice daily) or oral clopidogrel (75 mg once daily) at the
discretion of the operator. A loading dose of either drug was
not used, and therapy was either initiated the night before or
the day of the index procedure and continued for two to four
weeks following the procedure.
Vascular access sheaths were generally 8F, and were
removed following a successful procedure once the ACT
was #160 to 180 s. Manual groin compression was used to
achieve vascular hemostasis in all patients.
Study end points and definitions. Procedural success was
defined as all lesions dilated and stented with an angio-
graphic residual stenosis ,10% by visual estimate. Acute
stent thrombosis (AST) was defined as the occurrence of
stent thrombosis #24 h after the index procedure. Subacute
stent thrombosis (SST) was defined as stent closure .24 h
and #1 month following stent implantation.
A major adverse cardiac event (MACE) was defined as
any one of the following: a) myocardial infarction (Q-wave
or non–Q-wave); b) need for urgent repeat target vessel
revascularization (TVR); or c) cardiovascular death that
occurred during the period of hospitalization through one
month following the index coronary procedure.
Postprocedural myocardial infarction (MI) was defined as
the occurrence of typical ischemic chest pain of greater than
30 min duration with a creatine kinase (CK) elevation of
.2.5 times the upper limit of normal with an associated
increase in the MB fraction. There was no routine protocol
for acquisition of postprocedure CKs. All postprocedural
cardiac enzymes were obtained only for suspected recurrent
myocardial ischemia, manifested by recurrent postproce-
dural chest pain, hemodynamic instability, or new electro-
cardiographic changes of ischemia.
Urgent TVR was defined as a repeat PCI or coronary
artery bypass grafting (CABG) of the index stented artery
due to presumed recurrent ischemia manifested by recurrent
angina, arrhythmias or hemodynamic compromise.
Hemorrhagic complications were defined as a) clinically
evident bleeding from a vascular access site, gastrointestinal
or genitourinary site, and which resulted in a drop in
hemoglobin .4 g/dl or which required a blood-product
transfusion or surgical/ultrasound guided repair; b) retro-
peritoneal hemorrhage; or c) hemorrhagic stroke.
Length of hospitalization was assessed from the day of
the procedure until the day of hospital discharge. All end
points were assessed at hospital discharge and 30 days
following the index procedure and independently adjudi-
cated by investigators blinded to the antiplatelet therapy
received. All events were recorded through chart review,
hospital readmission data, follow-up patient questionnaires
and telephone calls.
Statistical analysis. Chi-square test and the Fischer exact
test were used for analysis of categorical variables when
appropriate, and the Student t-testing was used for analysis
Abbreviations and Acronyms
ACT 5 activated clotting time
AST 5 acute stent thrombosis
CABG 5 coronary artery bypass grafting
CK 5 creatinine kinase
GPIIb/IIIa 5 glycoprotein IIb/IIIa inhibitor
MACE 5 major adverse cardiac event
MI 5 myocardial infarction
PCI 5 percutaneous coronary intervention
SST 5 subacute stent thrombosis
TVR 5 target vessel revascularization
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of continuous variables. Confidence intervals (95%) were
determined when appropriate for each proportion. Multi-
variate logistic regression analysis was performed to deter-
mine significance of variables related to 30-day MACE.
Variables of the model included a) use of clopidogrel or
ticlopidine; b) clinical presentation; c) anticoagulant/
thrombolytic therapy; d) adjunctive administration of
GPIIb/IIIa inhibitors; e) ejection fraction ,40%; f) prior
history of MI, CABG or PTCA; g) vein graft stenting; h)
number of diseased vessels; i) gender; j) age .65; k)
hypertension; l) lipid status; and m) smoking history.
Statistical analysis was performed using SPSS software
(SPSS Institute).
RESULTS
Baseline demographics and clinical characteristics. Be-
tween March 1 and July 31, 1998, a total of 875 patients
underwent coronary stenting, of whom 514 (58.7%) re-
ceived clopidogrel-plus-aspirin and 361 (41.3%) received
ticlopidine-plus-aspirin. Of the 875 total patients, 576
(65.8%) received their antiplatelet therapy prior to the index
stent procedure, usually the night before or the morning of
the intervention. Of the 514 who received clopidogrel, 361
(70.2%) were pretreated, and 215 of 361 (59.6%)
ticlopidine-treated patients were pretreated. The remaining
patients received their thienopyridene after a successful
procedure.
There was a significant difference in the utilization of the
two drugs (p , 0.001) by coronary interventionalists. Of the
14 interventionalists who contributed patients during this
time period, 11 used the combination of clopidogrel-plus-
aspirin in over half their cases, while 3 interventionalists
used ticlopidine-plus-aspirin in over 50% of their cases (Fig.
1).
Although patients who received clopidogrel were signif-
icantly older as compared to those who received ticlopidine,
all other baseline demographics were similar between the
two groups (Table 1). Patients with acute coronary syn-
dromes accounted for 77.6% of the overall patient cohort,
with similar proportions of acute coronary syndrome pa-
tients receiving either clopidogrel-plus-aspirin (76.8%) or
ticlopidine-plus-aspirin (78.7%).
Procedural variables. The overall procedural success rate
was high and similar among patients who received clopi-
dogrel (99.6%) or ticlopidine (99.4%) therapy (Table 2).
Virtually all patients underwent primary stenting as their
planned strategy, with only one patient in each group having
a “bail-out” procedure. The distribution of stented vessels
was similar between the two groups. Adjunctive platelet
GPIIb/IIIa receptor inhibitors were utilized among 73.8%
Figure 1. Frequency of use of clopidogrel among interventionalists
during the study period, March 1, 1998, through July 31, 1998
(N 5 14 interventionalists).
Table 1. Patient Demographics: Clopidogrel Versus Ticlopidine
Population Characteristics
Variable Clopidogrel Ticlopidine
p
Value
N 514 361
Mean age (yrs) 65.1 6 11.8 62.7 6 12.4 0.003
Age .65 yrs 275 (53.5%) 166 (46.0%) 0.03
Men 318 (61.9%) 236 (65.4%) 0.32
Diabetes 119 (23.2%) 82 (22.7%) 0.93
Current smoker 321 (62.5%) 219 (60.7%) 0.62
Hypertension (.160/90 mm Hg) 113 (22.0%) 93 (25.8%) 0.20
Hypercholesterolemia (TC .240) 243 (47.3%) 184 (51.0%) 0.30
Prior MI 208 (40.5%) 153 (42.4%) 0.58
Prior CABG 111 (21.6%) 92 (25.5%) 0.19
Prior PCI 179 (34.0%) 116 (32.1%) 0.43
Diagnosis on admission NS
Acute MI in progress 39 (7.6%) 32 (8.9%)
Unstable angina or postinfarct 356 (69.3%) 252 (69.8%)
Stable angina 119 (23.1%) 77 (21.3%)
Prior thrombolytic therapy 40 (7.8%) 47 (13.0%) 0.28
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of all patients and in similar proportions of those in the two
treatment groups. There was no difference in the use of
adjunctive devices or intravascular ultrasound between the
two groups.
A total of 1,317 stents were implanted, with an average of
1.5 stents/patient deployed. Use of the AVE GFX ac-
counted for the majority of implanted stents (52%), fol-
lowed by Guidant’s Multilink (32.5%), and the J&J Crown
(11.7%). The remainder consisted of the Cook GR2 (2.2%),
Boston Scientific Radius (0.8%), J&J Palmaz-Schatz
(0.5%), and Medtronic Wiktor (0.4%). There was no
difference between the two groups regarding the utilization
of stent type. A greater proportion of patients who received
clopidogrel had $3 stents implanted as compared to the
ticlopidine-treated patients (13.6% vs. 6.9%, p , 0.013).
However, the stented segment length (18.3 6 5.0 mm vs.
18.3 6 5.1 mm, p 5 0.93) and the average size of the final
postdeployment balloon (3.35 6 0.51 mm vs. 3.8 6
0.51 mm: p 5 0.39) were similar between those patients
receiving clopidogrel or ticlopidine, respectively.
In-hospital and 30-day clinical outcomes. One-month
telephone follow-up was completed on 96.2% of the dis-
charged clopidogrel-treated and 94.5% of the ticlopidine-
treated patients (Table 3). There was no difference (p 5
0.15) in the average length of stay after coronary stenting
between patients treated with clopidogrel (2.2 6 1.1 days)
and those with ticlopidine (2.5 6 4.3 days).
Acute stent thrombosis was observed in only three pa-
tients, none of whom had received their first ordered dose of
clopidogrel. Two of the three patients were on abciximab
therapy at the time of the AST. One AST occurred in the
laboratory during the procedure, while the remaining two
occurred within 2 h following the index procedure. All three
patients sustained an MI (2, Q-wave; 1, non-Q-wave) and
one required urgent CABG within 24 h. All three survived
and were included for further analysis.
Subacute stent thrombosis occurred in two patients
(0.2%); one clopidogrel-treated (0.2%) at 12 days’ post-
stenting and one ticlopidine-treated (0.3%) patient at 20
days’ post-stenting (p 5 0.99).
There were seven in-hospital deaths (0.8%), which oc-
curred in similar proportions of patients in the two groups.
Of the five deaths occurring among the clopidogrel-treated
patients (0.9%), one was related to complications resulting
Table 2. Procedural Variables: Clopidogrel versus Ticlopidine
Procedural Variables
Variable Clopidogrel Ticlopidine p Value
Number vessels .60% NS
1 329 (64.0%) 231 (64.0%)
2 124 (24.1%) 75 (20.8%)
3 61 (11.9%) 55 (15.2%)
LV Ejection fraction 48.8 6 11.0 49.9 6 11.2 0.25
Bailout/failed procedure 2 (0.4%) 1 (0.3%) 0.87
Artery stented NS
RCA 194 (37.7%) 146 (40.4%)
LAD 179 (34.8%) 116 (32.1%)
LCX 130 (25.3%) 75 (20.8%)
LM 5 (0.9%) 2 (0.01%)
IM 2 (.003%) 2 (0.01%)
SVG 48 (9.3%) 32 (8.9%)
Final balloon size used/lesion 3.35 6 .51 3.38 6 0.51 0.39
Stents/patient 1.55 6 .84 1.42 6 0.74 0.016
Number stents implanted 0.013
1 318 (61.8%) 244 (67.6%)
2 126 (24.5%) 92 (25.5%)
3 or more 70 (13.6%) 25 (6.9%)
Mean stent length (mm) 18.3 6 5.0 18.3 6 5.1 0.93
#16 mm 375 (46.8%) 252 (48.8%)
17–24 mm 319 (39.8%) 188 (36.5%)
$25 mm 107 (13.4%) 76 (14.7%)
Adjunctive IIb/IIIa inhibitors 384 (74.7%) 262 (72.6%) 0.53
Adjunctive anticoagulation
Low molecular weight heparin 116 (22.6%) 97 (26.9%) 0.04
Coumadin 23 (4.5%) 20 (5.5%) 0.53
Adjunctive devices
Rotablator 7 (0.01%) 3 (0.01%) 0.67
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from SST, three were related to complications of their
presenting acute MI, and one died from surgical complica-
tions related to a severe vascular access site hemorrhagic
event. Two deaths occurred among the ticlopidine-treated
patients (0.6%). One resulted from a hemorrhagic stroke
after stenting, having received intravenous fibrinolytic ther-
apy, followed by the procedural administration of abciximab
and low molecular weight heparin following PCI. The
second death resulted from a primary ventricular arrhyth-
mia.
As shown in Table 3, there were no significant differences
observed between the clopidogrel- and ticlopidine-treated
patients in the 30-day combined end point (2.1% vs. 1.4%,
p 5 0.57), emergent CABG (0.4% vs. 0.3%, p 5 0.76),
repeat PCI (0.2% vs. 0%, p 5 0.99), nonfatal MI (1% vs.
0.6%, p 5 0.21) or death (0.9% vs. 0.6%, p 5 0.54),
respectively. To eliminate the possibility that the bias
inherent in each interventionalist prescribing in a nonran-
domized fashion, a statistical analysis of each operator’s
success and complication rate was completed. There was no
difference in the odds ratio of either procedural success or
adverse events for any of the 14 interventionalists.
Side effects/hemorrhagic complications. There was no
difference between the clopidogrel- or ticlopidine-treated
patients with respect to the frequency of skin rashes (1.2%
vs. 0.8%, p 5 0.95), or bruising or minor bleeding (0.4% vs.
0.3%, p 5 0.72), respectively. No patient reported signifi-
cant nausea, vomiting or diarrhea or had adverse hemato-
logic changes requiring cessation of therapy (Table 4).
Similarly, no significant difference existed in the rates of
packed red cell transfusions, vascular access site complica-
tions or hemorrhagic stroke between patients treated with
either drug. There was no difference in the frequency of
vascular access site complications among patients who
received oral antiplatelet therapy alone (2.4%), adjunctive
GPIIb/IIIa inhibitors either alone (2.6%), or with the use of
prior thrombolytic therapy and/or postprocedural anticoag-
ulation (2.2%).
Impact of platelet GPIIb/IIIa antagonists on clinical
outcome. Adjunctive GPIIb/IIIa inhibitors were utilized
in 85.9% of cases with a diagnosis of an MI, 73.3% of cases
with a diagnosis of unstable angina, and 58.4% of cases with
a diagnosis of stable angina. By multivariate analysis, the
only independent predictors of the 30-day composite end
point were a) age .65 years (p 5 0.041, odds ratio [OR] 5
3.31) and b) acute MI presentation (p 5 0.001, OR 5
6.00). There was no difference in the 30-day MACE rates
among patients receiving clopidogrel or ticlopidine regard-
less of the use of adjunctive GPIIb/IIIa receptor antago-
nists.
DISCUSSION
This study examined the clinical efficacy of two antiplatelet
regimens, clopidogrel or ticlopidine in combination with
aspirin, among a wide variety of patients undergoing coro-
nary stenting. Data collection started at the time of the
clinical release of clopidogrel. Importantly, these observa-
tional data reflect procedural and 30-day outcomes utilizing
contemporary clinical interventional practices employed
Table 3. 30-Day Clinical Outcomes: Clopidogrel Versus Ticlopidine
Outcomes
Clopidogrel
[95% CI]
Ticlopidine
[95% CI] p Value
Acute stent thrombosis 3 (0.6%)* 0 0.39
[0–1.2%]
Subacute stent thrombosis 1 (0.2%) 2 (0.3%) 0.99
[0–0.5%] [0–0.8%]
Death 5 (0.9%) 2 (0.6%) 0.54
[0.1%–1.8%] [0–1.3%]
Nonfatal myocardial infarction
Q-wave 2 (0.4%) 0 0.65
[0–0.9%]
Non-Q-wave 3 (0.6%) 2 (0.6%) 0.77
[0–1.2%] [0–1.3%]
Urgent revascularization
PCI 1 (0.2%) 0 0.99
[0–0.5%]
CABG 2 (0.4%) 1 (0.3%) 0.76
[0–0.9%] [0–0.8%]
MACE (MI, death, emergent revascularization) 11 (2.1%) 5 (1.4%)
[0.8%–3.4%] [0.1%–2.6%] 0.57
*None of three patients had received their first dose of clopidogrel.
CI 5 95% confidence interval; PCI 5 percutaneous coronary intervention; CABG 5 coronary artery bypass graft surgery;
MACE 5 major adverse cardiac event.
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during coronary stenting by a diverse group of intervention-
alists. This included standard procedural techniques of
routine high-pressure balloon stent deployment and utiliza-
tion of adjunct platelet GPIIb/IIIa receptor antagonists. In
addition, a broad spectrum of coronary artery disease pa-
tients were included in this analysis, with approximately
two-thirds of the population presenting with unstable an-
gina, 8% presenting with an acute MI, and 10% having
received thrombolytic therapy during their initial hospital
presentation.
We observed no significant differences in the procedural
success rates, length of hospital stay, and the incidence of
acute or subacute stent thrombosis among this broad spec-
trum of patients undergoing coronary stent procedures, who
received either clopidogrel or ticlopidine as adjunct anti-
platelet therapy. The 30-day composite end point (MACE)
of death, MI, or TVR, and hemorrhagic complications were
also observed in similar proportions of clopidogrel- and
ticlopidine-treated patients.
Role of combination antiplatelet therapy following cor-
onary stenting. A major development in coronary stenting
has been the recognition that aggressive anticoagulant
therapy is not necessary to prevent stent thrombosis, but
only contributes to excess hemorrhagic and vascular access
site complications. Combination antiplatelet therapy utiliz-
ing aspirin-plus-ticlopidine and current stent deployment
techniques have been shown to be superior to conventional
oral anticoagulation strategies and aspirin alone in reducing
stent thrombosis (11–15).
Observational data from three separate institutions have
provided suggestive data that the combination of
clopidogrel-plus-aspirin is effective in preventing stent
thrombosis and MACE following coronary stenting (16–
18). On the basis of reported observations of over a
thousand patients in these three studies, the rates of SST
(0.2% to 1.4%) and 30-day combined rates of death, MI and
TVR (0.8% to 1.6%) among patients undergoing coronary
stenting who received clopidogrel-plus-aspirin were highly
favorable and appeared similar to the historical rates for
patients who had received ticlopidine-plus-aspirin. Further-
more, the combined efficacy results from these analyses are
consistent with experimental animal models demonstrating
the efficacy of clopidogrel and aspirin as an effective anti-
platelet combination for the prevention of stent thrombosis
(19,20).
Recent studies have demonstrated that pretreatment of
coronary-stent patients with ticlopidine and aspirin is nec-
essary to enhance drug efficacy and to reduce the rates of
adverse postprocedural ischemic complications (21,22). The
three ASTs in our study occurred in individuals who had
received pretreatment only with aspirin but had not yet
received their first dose of a thienopyridine. Both the ISAR
and STARS trials initiated therapy with a thienopyridine
after completion of the angioplasty.
Only two patients experienced SST (0.23%); one
clopidogrel-treated patient (0.2%) occurring 12 days’ post-
procedure, and one ticlopidine-treated patient (0.3%) oc-
curring 20 days’ postprocedure. Both patients were receiving
their respective antiplatelet agent at the time of the throm-
botic event. The overall and individual drug rates of SST are
comparable to previously published reports of SST (0.2% to
0.8%) in which patients received ticlopidine-plus-aspirin
(11–13) and of the previously described clopidogrel obser-
vational reports (0.2% to 1.4%).
Study limitations. Although the present study was non-
randomized, the large treatment groups were well matched
for procedural and baseline demographics and operator
outcomes, thereby limiting the potential for selection bias.
The limitations of all observational data do, however, apply
to this present study. Given the low rate of MACE, the
ability to ascertain with statistical certainty the equivalence
of these two groups would require approximately 4,500
patients per group (alpha 5 0.05, beta 5 0.02, probability of
adverse event 5 0.01).
There was no routine collection of postprocedural cardiac
enzymes, hemoglobin or white blood cell counts during the
Table 4. In-Hospital Hemorrhagic Complications
Bleeding Complications
Outcome
Clopidogrel
[95% CI]
Ticlopidine
[95% CI] p Value
Any bleeding complication 28 (5.4%) 16 (4.4%) 0.35
[3.5%–7.4%] [2.3%–6.5%]
Hemorrhagic CVA 0 1 0.86
[0–0.8%]
Need for transfusion of PRBC 19 (3.7%) 11 (3.0%) 0.74
[2.1%–5.3%] [1.3%–4.8%]
Need for vascular access surgical repair 4 (0.8%) 3 (0.8%) 0.76
[0.01%–1.5%] [0%–1.8%]
Need for vascular access ultrasound guided
compression
8 (1.6%) 5 (1.4%) 0.94
[0.4%–2.6%] [0.2%–2.5%]
CI 5 95% confidence interval; CVA 5 cerebral vascular accident; PRBC 5 packed red blood cells.
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course of therapy through 30 days, producing an underrep-
resentation of postprocedural myocardial infarcts and lim-
iting the ability to detect potential differences in hemato-
logic toxicity between the two drugs. However, given the
similar procedural variables between the two treatment
groups (i.e., stented length, number of stents, among others)
the true incidence of postprocedural non–Q-wave myocar-
dial infarcts would likewise be expected to be similar
between the two drug groups.
The ability to distinguish the true hematologic differences
between the two thienopyridine drugs may have been
potentially affected by the relatively high use of GPIIb/IIIa
inhibitors in both groups. However, the use of GPIIb/IIIa
inhibition as an adjunct to coronary stenting does represent
the current state-of-the-art treatment (23).
Conclusions. The present study suggests that the combi-
nation adjunct therapy of clopidogrel and aspirin is an
effective antithrombotic regimen in preventing SST and
MACE after coronary stenting. Furthermore, clopidogrel is
associated with excellent clinical tolerability and low rates of
hemorrhagic complications.
Despite the high-risk baseline demographics and the
high utilization of platelet GPIIb/IIIa receptor antagonists
in our patient population, these findings appear comparable
to previous randomized coronary-stent studies utilizing the
combination of aspirin and ticlopidine with respect to stent
thrombosis and bleeding complications.
These findings complement prior studies suggesting the
importance of procedural pretreatment with thienopyridines
to attenuate platelet function during coronary stenting. The
randomized CLASSICS trial will report on the safety and
efficacy of two dosing regimens of clopidogrel in combina-
tion with aspirin relative to the combination of ticlopidine
with aspirin.
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